Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.

• Status: Completed
• Trial end date: 2013-11-11
• Target enrollment: 0
• Participant gender: All

Summary

This study is to define the pharmacokinetics and to evaluate the safety of BAY73-4506, 160 mg once daily administered orally as a single agent in Japanese patients with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer

Criteria

Inclusion Criteria:

• Male or female Japanese patients >/= 18 years

• Histologically or cytologically confirmed solid tumors

• ECOG-PS 0 - 1

• Adequate bone marrow, liver and renal function

Exclusion Criteria:

• Uncontrolled hypertension

• Patients with severe renal impairment or on dialysis

• Patients with seizure disorder requiring anticonvulsant medication

• Known or suspected allergy to the investigational agent.